Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade

J Hypertens. 2005 Sep;23(9):1717-24. doi: 10.1097/01.hjh.0000176787.04753.ee.

Abstract

Objective: To determine the effects of age and dual endothelin (ET)A/ETB receptor antagonism (bosentan) on aortic matrix metalloproteinase (MMP) abundance and tissue inhibitor of metalloproteinase (TIMP) expression in normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR).

Methods: Male SHR and control WKY rats were randomly assigned to receive placebo or bosentan (100 mg/kg per day) for 3 months. Animals were killed under terminal anaesthesia at either 20 weeks (adult) or 17-20 months (senescent). Aortic gelatinase activity was determined by zymography, whereas MT-1 MMP and TIMP-1 expression were assessed by immunoblotting.

Results: In WKY rats, aortic MMP-2 but not proMMP-2 activity was 3.6-fold higher (P < 0.02) in the senescent compared with the adult group. TIMP-1 (twofold) and MT-1 MMP (3.8-fold) expression increased (P < 0.05) with age in the WKY groups. Short-term hypertension (adult SHR versus adult WKY) increased MMP-2 to 74.7 +/- 14.1 from 18.9 +/- 3.5 arbitrary units (AU) (P = 0.0012), but did not alter proMMP-2 activity. This increased further on progression to chronic hypertension (117.4 +/- 12.2 versus 74.7 +/- 14.1 AU; P < 0.02). Bosentan decreased MMP-2 (78.9 +/- 3.8 versus 117.4 +/- 12.2 AU; P = 0.014) and proMMP-2 activity (P < 0.006) in the senescent SHR group.

Conclusion: Ageing and the development/progression of hypertension are associated with increased MMP-2 activity in the aorta, which is consistent with ongoing remodelling of the vasculature. However, the underlying mechanisms regulating MMP-2 abundance in ageing and hypertension appear to be divergent, as MT-1 MMP expression is differentially altered. Dual ETA/ETB receptor antagonism did not alter the age-dependent increase in aortic MMP activity in normotensive rats. However, bosentan decreased pro and active MMP-2 activity in senescent SHR rats, indicating that ET modulates late events in vascular remodelling in hypertension.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging*
  • Animals
  • Antihypertensive Agents / pharmacology
  • Aorta, Thoracic / enzymology
  • Blotting, Western
  • Bosentan
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Endothelin Receptor Antagonists*
  • Endothelium, Vascular / enzymology
  • Enzyme Precursors / metabolism
  • Gelatinases / metabolism
  • Hypertension / metabolism*
  • Male
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinases / metabolism*
  • Metalloendopeptidases / metabolism
  • Microscopy, Fluorescence
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Receptor, Endothelin A / genetics
  • Receptor, Endothelin A / metabolism
  • Receptor, Endothelin B / genetics
  • Receptor, Endothelin B / metabolism
  • Receptors, Endothelin / genetics
  • Receptors, Endothelin / metabolism
  • Reference Standards
  • Sulfonamides / pharmacology

Substances

  • Antihypertensive Agents
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Endothelin Receptor Antagonists
  • Enzyme Precursors
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • Receptors, Endothelin
  • Sulfonamides
  • Gelatinases
  • Matrix Metalloproteinases
  • Metalloendopeptidases
  • progelatinase
  • Matrix Metalloproteinase 2
  • Bosentan